| abstract |
The disclosure relates to a fused heterocyclic derivative of the formula (I), wherein the variables R1-R4, z, A, Q, X and Y are as defined in the specification. 4-{ 2-[4-(2-Fluoro-benzyloxy)-phenyl]-6,7-dihydro-4H-furo[3,2-c]pyridine-5-yl} -butyric acid is a typical example of said fused heterocyclic derivative. These compounds of formula (I) are modulators of the S1P receptor (Sphingosine-1-phosphate receptor). More specifically, they are agonists of S1P5. The compounds have therapeutic use in treatment of neurodegenerative disorder, in particular selected from a cognitive disorder, Alzheimer’s disease, (vascular) dementia, Nieman’s Pick disease, and cognitive deficits in schizophrenia, obsessive-compulsive behaviour, major depression, autism, multiple sclerosis and pain, and specifically a cognitive disorder, such as age-related cognitive decline. |